Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis by Guyot, Patricia et al.
RESEARCH ARTICLE Open Access
Abatacept with methotrexate versus other
biologic agents in treatment of patients with
active rheumatoid arthritis despite methotrexate:
a network meta-analysis
Patricia Guyot
1, Peter Taylor
2, Robin Christensen
3, Louisa Pericleous
4, Coralie Poncet
5, Maximilian Lebmeier
4,
Pieter Drost
6 and Gert Bergman
1*
Abstract
Introduction: The goal of this study was to compare the efficacy in terms of Health Assessment Questionnaire
change from baseline (HAQ CFB), 50% improvement in American College of Rheumatology criterion (ACR-50) and
Disease Activity Score in 28 joints (DAS28) defined remission (< 2.6) between abatacept and other biologic disease
modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) who have inadequate
response to methotrexate (MTX-IR).
Methods: A systematic literature review identified controlled trials investigating the efficacy of abatacept (three
studies), etanercept (two studies), infliximab (two), adalimumab (two), certolizumab pegol (two) ritixumab (three),
and tocilizumab (two) in MTX-IR patients with RA. The clinical trials included in this analysis were similar with
respect to trial design, baseline patient characteristics and background therapy (MTX). The key clinical endpoints of
interest were HAQ CFB, ACR-50 and DAS28 < 2.6 measured at 24 and 52 weeks. The results were analysed using
network meta-analysis methods that enabled calculation of an estimate for expected relative effect of comparative
treatments. Analysis results were expressed as the difference in HAQ CFB score and odds ratio (OR) of achieving an
ACR-50 and DAS28 response and associated 95% credible intervals (CrI).
Results: The analysis of HAQ CFB at 24 weeks and 52 weeks showed that abatacept in combination with MTX is
expected to be more efficacious than MTX monotherapy and is expected to show a comparable efficacy relative to
other biologic DMARDs in combination with MTX. Further, abatacept showed comparable ACR-50 and DAS28 < 2.6
response rates with other biologic DMARDs at 24 and 52 weeks, except for ACR-50 compared to certolizumab
pegol at 52 weeks and for DAS28 < 2.6 compared to tocilizumab at 24 weeks. Sensitivity analyses confirmed the
robustness of the findings.
Conclusions: Abatacept in combination with MTX is expected to result in a comparable change from baseline in
HAQ score and comparable ACR-50 and DAS28 < 2.6 response rates in MTX-IR patients compared to other
approved biologic agents.
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Rheumatoid arthritis (RA) is a chronic, disabling sys-
temic inflammatory disorder, with immune-mediated
attacks of the synovial joints. Disease-modifying anti-
rheumatic drugs (DMARDs) alleviate the symptoms of
RA and have the potential to slow or stop disease pro-
gression [1-3]. DMARDs are classified into two types:
conventional and biologic. European Guidelines recom-
mend that methotrexate (MTX), a conventional
DMARD, is included in the first-line treatment strategy
for active RA as soon as possible after diagnosis [4]. In
patients with an insufficient response to treatment with
MTX and/or other conventional DMARDs, biologic
DMARDs designed to target specific elements of the
immune system involved in the inflammation and
damage to joints should be combined with MTX to
improve the outcome, in particular TNF inhibitors [4].
Currently licensed TNF inhibitors for patients with RA
showing active disease despite MTX therapy include
infliximab [5], etanercept [6], adalimumab [7], certolizu-
mab pegol [8] and golimumab [9]. Other licensed biolo-
gic agents with alternative mechanisms of action include
tocilizumab [10] and abatacept [11]; also rituximab [12]
was under evaluation for approval in this patient popu-
lation at the time of this analysis.
Abatacept is the first in class of biologic DMARDs and
acts by selectively modulating an essential co-stimulatory
pathway needed for T-cell activation, thus inhibiting the
inflammatory process upstream in the cascade of inflam-
matory events of importance in the pathology of RA [13].
The effectiveness of abatacept has been demonstrated in
a series of randomised controlled trials [14-18]. Ideally,
in order that decisions on treatment options could be
made based on firm clinical evidence, the comparative
efficacy of each and every treatment option would be
known. However, given the lack of head-to-head data for
direct comparison, network meta-analyses are necessary
in order to calculate the expected efficacy of biologic
DMARDs. Indirect comparisons of interventions can be
made through a common comparator [19].
Our objective was to perform a network meta-analysis
for abatacept following a systematic review of the pub-
lished clinical evidence of abatacept and all other exist-
ing biologic DMARDs available, licensed in Europe for
patients that failed to respond to MTX or in the process
of obtaining such a license. The aim of the study was to
estimate the relative efficacy of abatacept in combination
with MTX in Health Assessment Questionnaire change
from baseline (HAQ score CFB) compared to other rele-
vant biologic DMARDs plus MTX in the treatment of
patients with RA with insufficient response to MTX. As
a secondary aim, we studied the efficacy in terms of
response rates of the American College Rheumatology
Criterion for 50% improvement (ACR-50) and in Dis-
ease Activity Score in 28 joints (DAS28) defined remis-
sion (< 2.6).
Materials and methods
Systematic review
A protocol was developed to define the search strategy
and a systematic review performed consecutively to
identify those randomised controlled trials (RCTs),
which investigated the efficacy of biologic DMARDs
licensed to treat RA with insufficient response to at
least one conventional DMARD. MEDLINE and
EMBASE databases were searched simultaneously using
Datastar. Further searches were undertaken for the
Cochrane Library, the American College of Rheumatol-
ogy (ACR) and European League Against Rheumatism
(EULAR) conferences, and the technology appraisals for
the UK. Searches included a combination of free-text
and Medline Subject Headings (MeSH) terms for ‘dis-
ease terms’ with ‘drug names’,a n dw e r el i m i t e dt o
‘human’ RCTs published, in English, between January
1980 and January 2010.
The systematic review was performed by two research-
ers, with discussions between the two to come to agree-
ment in case of discrepancies. The full-text articles were
assessed for inclusion according to the following selec-
tion criteria: (1) treatment combinations of MTX with
abatacept, adalimumab, certolizumab, etanercept, goli-
mumab, infliximab, rituximab or tocilizumab in compari-
son with each other or Placebo + MTX; (2) RA patients
with an inadequate response or intolerance to previous
treatment with at least one conventional DMARD (MTX,
sulfasalazine, leflunomide, azathioprine, gold salts or
minocycline); (3) clinical endpoints of HAQ CFB [20,21],
American College of Rheumatology Criterion of 50%
i m p r o v e m e n t( A C R - 5 0 )[ 2 2 ]a n dr e m i s s i o nd e f i n e db ya
Disease Activity Score including a 28-joint count less
than 2.6 (DAS28 < 2.6) [23]; at 24 and/or 52 weeks.
Data collection
For each selected study, the details of design, selection
criteria, study population characteristics, interventions,
outcome measures, length of follow-up and results were
extracted and recorded in data extraction forms. The
data extraction was performed by one researcher and
reviewed by another; meaning, effectively, that the sec-
ond reviewer traced back every value/number/comment
to the original full text report and validated the
extracted data.
Network meta-analyses
The search strategy was developed in order to capture all
the relevant studies; but to ensure more coherent network
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were restricted as follows: (1) only recommended dosages
licensed for treatment in Europe [5-12] and (2) only RA
patients with an inadequate response or intolerance to
MTX. The quantitative results of the different interven-
tions from the studies identified were combined using
Bayesian mixed treatment comparison techniques [19]. All
analyses were performed using a non-informative prior
distribution and, depending on the heterogeneity as
assessed by the goodness-of-fit test based on the residual
deviance [19], either a fixed effect or a random effects
model was chosen. Analyses were performed for the end-
points of HAQ CFB (continuous outcome), ACR-50 and
DAS28 < 2.6 response rates (dichotomous outcomes)
using placebo (in combination with MTX) as the common
comparator. The network meta-analysis results present
estimates of the differences in mean HAQ CFB, and esti-
mates of odds ratio (OR) for ACR-50 and DAS28 < 2.6,
for each biologic agent compared with placebo and for
each pairwise combination of biologic agents. By using the
average absolute placebo response (calculated as the
weighted mean placebo response based on all included
trials) as a baseline, the relative efficacy of each treatment
compared with placebo was adjusted to obtain expected
absolute mean HAQ CFB and its 95% credible interval
(95% CrI), and expected absolute probability of response
and its 95% CrI, for ACR-50 and DAS28 < 2.6, for each
biologic agent. For the relative efficacies as well as for the
absolute responses, the point estimates reflect the most
likely value for the parameter considered and the 95%
credible intervals state that there is a 95% posterior prob-
ability that the parameter lies between the two values of
the interval.
For the HAQ CFB analyses, the standard deviation
was directly extracted from the publications where pos-
sible. When the standard deviation was not reported, it
was estimated based on other statistics that allow calcu-
lation or estimation of the standard deviation (for exam-
ple, confidence interval, standard error, t-value, P-value,
F value). When no information about the uncertainty
was available, the average of all the other standard
deviations explicitly reported was imputed to the miss-
ing standard deviation, enabling integration of all the
data available. The feasibility of the network meta-analy-
sis was evaluated by means of a qualitative assessment
of the comparability of the studies in terms of study
design, treatments evaluated, patient population and
q u a l i t yo ft h en e t w o r ko fs t u dies. Differences across
trials might act as effect modifiers and thereby poten-
tially violate the similarity and consistency assumptions
associated with network meta-analyses. Violation of
these assumptions might introduce bias in the relative
treatment effect estimates. Analyses were performed
with WinBUGS 1.4 statistical software.
Base-case and sensitivity analyses
The base case analysis of a network meta-analysis
includes the broadest available evidence base corre-
sponding to the question evaluated, under the condition
of comparability for effect modifiers’ characteristics. As
the firm definition of such a case is often challenging,
we pre-specified in the protocol that scenario analyses
would be conducted along the base case, with an exact
definition of these scenarios elaborated after the qualita-
tive assessment of the included studies.
Results
Systematic review
The systematic review identified 1,551 potentially rele-
vant studies, of which 29 publications, including 2 Clini-
cal Study Reports (CSRs), 1N I C Es u b m i s s i o na n d4
abstracts, were identified to be relevant. The study selec-
tion process is summarised in Figure 1. The 29 docu-
ments identified by the literature search included 16
individual studies for abatacept [14-18], adalimumab
[24,25], certolizumab pegol [26-29], etanercept [30-32],
golimumab [33,34], infliximab [15,35,36], rituximab
[37-41] and tocilizumab [42-44]. Each comparison was
supported by at least one pivotal trial, but not all trials
reported findings for the HAQ CFB, the ACR-50 and
DAS28 < 2.6 responders at either or both 24-week and
52-week follow-ups. All 16 included studies were rando-
mised, double-blind and placebo-controlled.
Study design and patient characteristics
As presented in Table 1, most studies were generally
comparable in design, although differences were identi-
fied regarding patients not responding to treatment; the
adalimumab studies included an early escape for non-
responders [24] while the certolizumab pegol studies
specifically withdrew patients who did not show an
ACR20 response at weeks 12 and 14 [26-29]. Further-
more, the golimumab [33,34] and tocilizumab [43,44]
studies provided rescue therapy for patients who did not
achieve at least 20% improvement in both Tender Joint
Count (TJC) and Swollen Joint Count (SJC) by week 16.
The TEMPO trial [30,31] did not meet the inclusion cri-
teria defined for the network meta-analyses; the study
population was not comprised solely of patients diag-
nosed with RA showing an inadequate response to
MTX. The SERENE study evaluating rituximab [37,38]
and the LITHE study evaluating tocilizumab [42] were
only publicly available in abstract format. Since no char-
acteristics on design and patients were reported, no full
evaluation of the comparability could be performed for
these studies.
An overview of the baseline patient characteristics is
provided in Table 2. All studies reported similar HAQ
scores at baseline, except for the study by Kremer et al.
Guyot et al. Arthritis Research & Therapy 2011, 13:R204
http://arthritis-research.com/content/13/6/R204
Page 3 of 182005 [16], which presented a lower mean HAQ baseline
value. This difference was likely to be due to the use of
the modified HAQ (mHAQ) instead of the traditional
Health Assessment Questionnaire Disability Index. Both
instruments are strongly correlated with a Pearson cor-
relation coefficient of 0.88 [45], so the difference in the
instruments is assumed to have no impact on the rela-
tive treatment effect. For golimumab, the main publica-
tion [33] reported median and IQR data, instead of the
expected means and SD, suggesting that data were not
normally distributed. This study also included patients
with lower swollen joint counts, a lower CRP level and
shorter disease duration than most of the other studies
in the network meta-analysis. Certolizumab pegol
[26-29] and etanercept [30,31] included patients with a
shorter disease duration compared to other identified
trials. No information about the patient characteristics
were provided for the SERENE and the LITHE studies.
The reported data for HAQ change from baseline at
24 and 52 weeks are presented in Table 3. A network
meta-analysis was performed including 14 studies in the
base case. Etanercept was evaluated in only two trials:
Weinblatt 1999 [32] and TEMPO trial. As Weinblatt
1999 is a relatively small study (89 patients included), it
was decided to retain the TEMPO trial in the base case
analysis and to evaluate the impact of exclusion in a
Abstracts excluded (1434)  
Not randomized controlled trials (757) 
Not rheumatoid arthritis patients (220) 
Not adult patient population (61) 
Intervention or comparison out of scope (219) 
Outcome not of interest (161) 
Other (16) 
Potentially relevant full text publications (117) 
Full text publications excluded (96) 
Study design out of scope (25) 
Outcomes not of interest (28) 
Population out of scope (26) 
Intervention out of scope (8) 
Other (7) 
Studies pending (2) 
Included for data extraction (29): 
Full publications (21), clinical study reports (2: AIM and ATTEST), Certolizumab submission (1), abstracts (5) 
 
Abstracts (5), reports (2) and submissions (1) identified from other information sources: 
NICE, BMS, ACR and EULAR 
Potentially relevant abstracts (1551) identified for retrieval based on systematic search in Datastar (Embase, 
Medline, Medline in progress) and Cochrane RCT Library. 
Final RCTs included (16): 
Abatacept (3), Etanercept (2), Golimumab (1), Infliximab (2), Adalimumab (2), Certolizumab (2), Rituximab 
(3), Tocilizumab (2). 
1 RCT contains both abatacept and infliximab 
Two studies were only available in abstract format 
 
Figure 1 Selection of included publications. CFB, change from baseline; HAQ, Health Assessment Questionnaire; MTX, Methotrexate.
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Trial
(reference)
Compared
interventions
Trial design;
Patient population
Inclusion criteria Endpoints Study period
Exclusion criteria
Abatacept studies
AIM trial
[14,18]
PBO + MTX;
ABA 10 mg/kg
every four weeks
+ MTX
Phase 3 RCT; Active
RA despite MTX
Met ACR criteria, > = 18 years, RA for
> = 1 year, > = 10 SJC, > = 12 TJC,
CRP > = 10.0 mg/L, MTX (≥ 15 mg/
week) for ≥ 3 months with stable
dose for 28 days prior to enrolment
ACR20 at six
months; HAQ-DI (≥
0.3); CFB in joint
erosion score at one
year
Nov ‘02 to Oct’ 04; 52
weeks
Positive tuberculin skin test
Kremer et
al. 2005,
Kremer et
al. 2003
[16,17]
PBO + MTX;
ABA 2 mg/kg
every four weeks
+ MTX;
ABA 10 mg/kg
every four weeks
+ MTX
Phase 3 RCT; Active
RA despite MTX.
Met ACR criteria, > = 10 SJC, > = 12
TJC, CRP > 1 mg/dl, MTX (10 to 30
mg/week) for > = 6 months with
stable dose for 28 days prior to
enrolment
ACR20 at six months Date n/s; 52 weeks + 6
months
n/s
ATTEST trial
[15]
PBO + MTX;
ABA 10 mg/kg
every four weeks
+ MTX;
INF 3 mg/kg every
eight weeks +
MTX
RCT, double-dummy,
PBO and active (INF)-
controlled; RA and
MTX-IR
Met ACR criteria, > = 18 years, RA for
> = 1 year, > 10 SJC, > 12 TJC, CRP >
1 mg/dl, MTX > 15 mg/week for > 3
months prior to randomisation, other
DMARDs washed out
Reduction in DAS28
with abatacept vs
placebo at six
months
Feb ‘05 to June ‘06; 52
weeks
PBO arm = PBO for six
months followed by ABA
Prior experience with abatacept or an
other approved biologic RA therapy,
failed on > 4 conventional DMARDs
Adalimumab studies
ARMADA
[25]
PBO + MTX;
ADA 20 mg every
other week + MTX;
ADA 40 mg every
other week + MTX;
ADA 80 mg every
other week + MTX
RCT; Active RA
despite MTX
Met ACR criteria; > = 18 years, > 9
TJC, > 6 SJC, MTX for > = 6 months
and stable weekly dose for > = 4
weeks before enrolment, failed
treatment with > = 1 DMARD besides
MTX, but not > 4 DMARDs
ACR20 Date n/s; 24 weeks
Prior anti-CD4 therapy or TNF-a
antagonists, history of active listeriosis
or mycobacterial infection, any major
infection
DE019 [24] PBO + MTX;
ADA 20 mg
weekly + MTX;
ADA 40 mg every
other week + MTX
RCT; Active RA treated
with MTX.
Met ACR criteria; > = 18 years, > = 9
TJC, > = 6 SJC, CRP > 1 mg/dl, either
rheumatoid factor positivity or > = 1
joint erosion on radiographs of hands
+ feet, MTX for > = 3 months at
stable dose of 12.5 to 25 mg/week for
> = 4 weeks
ACR20 at week 24 Date n/s; 52 weeks
Prior anti-CD4 therapy or TNF
antagonists;
history of: other active inflammatory
arthritide, active listeriosis/
mycobacterial infection, lymphoma/
leukemia within five years; any major
infection
Certolizumab Pegol studies
RAPID I
[26,27,29]
PBO + MTX;
CZP 200 mg every
other week + MTX;
CZP 400 mg every
other week + MTX
Phase 3 RCT; Active
RA with MTX-IR
> = 18 years, active RA for > = 6
months + < 15 years, > = 9 TJC + SJC
with either ESR > = 30 m/hour or CRP
> 15 mg/l, MTX for > = 6 months
with a stable dosage of > = 10 mg/
week for > = 2 months.
ACR20 at week 24;
mean CFB in
modified total Sharp
score at week 52
Feb ‘05 to Oct’ 06; 52
weeks.
ACR20 non-responders at
weeks 12 + 14 were
withdrawn
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History of: tuberculosis, malignancy;
PPD positive skin test; biologic
therapy within 6 months, prior failure
to respond to anti-TNF agent
RAPID II
[28,29]
PBO + MTX;
CZP 200 mg every
other week + MTX;
CZP 400 mg every
other week + MTX
Phase 3 RCT; Active
RA despite > = 6
months of MTX
Met ACR criteria, > 18 years, RA > 6
months duration but < 15 years, MTX
for > 6 months (stable dose > 10 mg/
week for > 2 months at baseline)
ACR20 at week 24 June ‘05 to Sept’ 06; 24
weeks
ACR20 non-responders at
weeks 12 + 14 were
withdrawn
Biologic agent in previous six months,
severe reaction to biologic agents, no
response to previous anti-TNF therapy,
history of tuberculosis, PPD positive
skin test
Etanercept studies
Weinblatt et
al. 1999
[32]
PBO + MTX;
ETN 25 mg 2x
week + MTX
Double-blind,
randomised; Active
RA despite > = 6
months of MTX
Met ACR criteria, > = 18 years, > = 6
SJC + TJC, MTX for > = 6 months at
stable dose of 15 to 25 mg/week for
last 4 weeks, discontinued
sulfasalazine + hydroxychloroquine >
= 2 weeks + DMARDs other than MTX
> = 4 weeks prior to study
ACR 20 at 24 weeks Date n/s; 24 weeks
n/s
TEMPO
[30,31]
PBO + MTX;
ETN 25 mg 2x
week;
ETN 25 mg 2x
week + MTX
Randomised, double-
blind, parallel group
study; RA patients
with DMARD-IR
Met ACR criteria, > = 18 years, active
disease for 6 months-20 years, > 10
SJC, > 12 painful joints, IR to > = 1
DMARD other than MTX, previous
MTX (without toxic effects/lack of
response), no MTX within 6 months of
enrolment
ACR response (ACR-
N) AUC for the first
24 weeks
Oct ‘00 to July’ 01; 52
weeks
Prior therapy with ETN or other TNF
antagonists, immunosuppressive drugs
within 6 months; investigational drug
or biologic agent within 3 months,
any other DMARDs or corticosteroid
within 4 weeks, presence of relevant
co morbidity
Golimumab studies
GO-
FORWARD
[33,34]
PBO + MTX;
GOL 100 mg every
four weeks;
GOL 50 mg every
four weeks + MTX;
GOL 100 mg every
four weeks + MTX
Phase 3 RCT; active
RA despite MTX
Met ACR criteria, > 18 years, RA > = 3
months, tolerated stable MTX dose of
15-25 mg/week for > = 3 months
prior to screening, > = 4 SJC & TJC,
met the tuberculosis screening criteria
ACR20 at week 14
and improvement
from baseline in
HAQ-DI score at
week 24.
Dec ‘05 to Sept’ 07; 52
weeks. At week 16,
patients < 20% CFB in TJC
and SJC had medication
adjusted
Hypersensitivity to GOL, previous anti-
TNF agent, RTX, natalizumab, cytotoxic
agents, anakinra, DMARDs other than
MTX, corticosteroids within four
weeks, alefacept or efalizumab within
three months.
Infliximab studies
ATTRACT
[35,36]
PBO + MTX;
INF 3 mg/kg every
eight weeks +
MTX;
INF 3 mg/kg every
four weeks + MTX;
INF 10 mg/kg
every eight weeks
+ MTX;
INF 10 mg/kg
every four weeks
+ MTX
International Phase 3
RCT; Active RA
despite MTX
Met ACR criteria, > = 6 SJC + TJC,
MTX for > = 3 months not stopped
for > 2 weeks, MTX at stable dose >
12.5 mg/week for > = 4 weeks, oral
corticosteroids or NSAIDs on stable
dose for > = 4 weeks
ACR20 at week 30 Date n/s; 54 weeks
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DMARD (not MTX) or non-oral
corticosteroids in four weeks before
screening, alkylating agents, any other
agent to reduce TNF, allergic to
murine proteins, serious infections in
previous three months, chronic
infectious disease
Rituximab studies
DANCER
[39,40]
PBO + MTX;
RTX 500 mg x2
injections + MTX;
RTX 1,000 mg x2
injections + MTX
Phase 2b international
RCT, double-dummy;
Active RA with
DMARD-IR and MTX-
IR.
Met ACR criteria, 19 to 79 years, RA >
6 months, MTX at 10 to 25 mg/week
for > = 12 weeks before
randomization, stable dose for last 4
weeks, > 8 SJC + TJC, either ECR > =
28 mm/hour or CRP > = 1.5 mg/dl, IR
to 1 to 5 DMARDs (other than MTX)
and/or biologic agents discontinued >
= 4 weeks before randomization and
INF, ADA, leflunomide > = 8 weeks
before randomization
ACR20 for RF-
positive patients at
week 24
Date n/s; 24 weeks
Significant systemic involvement
secondary to RA, other illnesses or
laboratory abnormalities, severe
allergic or anaphylactic reactions to
monoclonal antibodies, previous
treatment with RTX or any
lymphocyte-depleting therapies,
recurrent significant infection
N/S
Strand et al.
2006 [41]
PBO + MTX;
RTX 1,000 mg x2
injections;
RTX 1,000 mg x2
injections +
cyclophosphamide;
RTX 1,000 mg x2
injections + MTX
RCT; Active RA
despite MTX
Met ACR criteria, > 21 years, MTX > =
10 mg/week, > = 8 SJC + TJC, CRP >
= 15 mg/l and/or ESR > = 28 mm/h,
and/or morning stiffness > 45
minutes, plasma rheumatoid factor
level > 20 IU/ml
ACR 50 at week 24 Date n/s; 48 weeks
Other autoimmune disease, ARA
functional class IV disease, active
rheumatoid vasculitis, history of
systemic diseases associated with
arthritis, chronic fatigue syndrome,
serious and uncontrolled coexisting
diseases
SERENE
[37,38]
PBO + MTX;
RTX 500 mg x2
injections + MTX;
RTX 1,000 mg x2
injections + MTX
Phase 3 RCT; Active
RA with MTX-IR and
naïve to prior biologic
therapy
≥ 8 SJC + TJC, elevated CRP (≥ 0.6
mg/dL) and/or ESR (≥ 28 mm/h)
despite MTX for ≥ 12 wks
ACR20 at week 24 Date n/s; 48 weeks
N/S
Tocilizumab studies
OPTION
[43,44]
PBO + MTX;
TCZ 4 mg/kg
every four weeks
+ MTX;
TCZ 8 mg/kg
every four weeks
+ MTX
Phase 3 RCT, parallel
group; RA with MTX-
IR
Met ACR criteria, adults, RA > 6
months, MTX-IR, > = 6 SJC, > = 8 TJC,
CRP > 10 mg/L or ESR > = 28 mm/h,
MTX for > = 12 weeks before start of
study (stable dose of 10 to 25 mg/
week for > = 8 weeks),
discontinuation of other DMARDs:
leflunomide > = 12 weeks, anakinra >
= 1 week, etanercept > = 2 weeks,
infliximab or adalimumab > = 8
weeks prior to start of study
ACR20 at 24 weeks Date n/s; 24 weeks. At
week 16, patients < 20%
CFB in TJC and SJC were
eligible for rescue therapy
with TCZ 8 mg/kg
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sion of the SERENE and LITHE studies in sensitivity
analyses in anticipation of the full text publications.
Since comparability of the study design characteristics
and the patients’ characteristics could not be performed,
the results need to be interpreted with this limitation in
mind. Other observed differences between trials could
not be explored in scenario analyses, as excluding these
studies would have removed the treatments from the
analysis.
Network Meta-analysis results (Tables 4 and 5)
HAQ change from baseline at 24 and 52 weeks
At 24 weeks, all biologic agents in combination with
MTX were found to be more effective than placebo in
combination with MTX in improving functional status
(HAQ CFB). Small numerical differences were observed
in favor of abatacept over etanercept, infliximab, rituxi-
mab and tocilizumab. The adjusted absolute mean HAQ
change from baseline varied between -0.48 and -0.67 for
the biologic agents considered. Abatacept showed com-
parable efficacy compared to other biologics at 24 weeks
(absolute mean HAQ change from baseline of -0.58). At
52 weeks, the findings were in line with those at 24
weeks. All biologics demonstrated a higher reduction in
HAQ score compared to placebo and a comparable effi-
cacy relative to the other biologic agents, with a trend in
favor of abatacept over infliximab (-0.11, 95% CrI: -0.22;
0.01)).
Figure 2 illustrates each pairwise relative efficacy of all
biologic agents compared to placebo at 24 and 52
weeks.
ACR-50 response rates at 24 and 52 weeks
At 24 weeks, all biologic agents demonstrated a higher
proportion of ACR-50 responders than placebo, and
abatacept is expected to demonstrate comparable ACR-
50 response rates as to the other biologic agents. The
expected proportion of patients with ACR-50 response
was estimated to be 31.7% (95% CrI: 15.9%; 50.6%) for
abatacept, which is higher than those for placebo
(11.9%, 95% CrI: 9.7%; 14.0%) and comparable to the
other biologic agents (expected proportions between
26.0% and 57.3%). At 52 weeks, abatacept is expected to
result in a higher proportion of responders than placebo
and comparable response rates to other biologic agents
except for certolizumab pegol (OR:0.51, 95% CrI: 0.26;
0.96) although these results need to be interpreted with
caution due to the earlier described difference in trial
design. The expected proportion of ACR-50 responders
for abatacept was slightly higher (35.4%, 95% CrI: 27.3%;
43.3%) than those at 24 weeks.
DAS28 defined remission (< 2.6) at 24 and 52 weeks
At 24 weeks, no data were available for adalimumab and
rituximab. Abatacept was found to result in more
patients with DAS28 define dr e m i s s i o nt h a np l a c e b o ,
with an OR of 4.77 (95% CrI: 1.60; 15.78). Abatacept is
expected to be less efficacious than tocilizumab, but
showed findings comparable to all other biologic agents.
The expected proportion of patients under remission at
24 weeks amongst the biologics ranged from 6.9% to
71.0%. At 52 weeks, data were only available for inflixi-
mab, etanercept and abatacept. Abatacept was found to
result in more DAS28 responders than the placebo and
in comparable remission rates compared to infliximab
and etanercept. The expected proportion of patients
under remission at 52 weeks for abatacept was higher
(40.2%, 95% CrI: 10.4%; 80.3%) than at 24 weeks.
Sensitivity analyses
The TEMPO trial was included in the base case analy-
sis as it was the pivotal trial for etanercept in this
patient population. However, the TEMPO trial
Table 1 Overview of trial designs (Continued)
other autoimmune diseases,
significant systemic involvement
secondary to RA, functional class IV
RA, inflammatory joint disease other
than RA, recurrent infections,
active liver disease, anti-TNF agent
failure
Not stated
LITHE [42] PBO + MTX;
TCZ 4 mg/kg
every four weeks
+ MTX;
TCZ 8 mg/kg
every four weeks
+ MTX
Phase 3 RCT, double-
blind; RA with MTX-IR
N/S CFB in Genant-
modified Sharp
score and AUC in
the HAQ-DI at Week
52
two years
A switch to blinded rescue
treatment was available at
weeks 16 and 28, if
required.
ABA, abatacept; ADA, adalimumab; ARA, American Rheumatism Association; AUC, area under the curve; CFB, change from baseline; CZP, certolizumab pegol;
DMARD-IR, inadequate response to DMARD; ETN, etanercept; GOL, golimumab; INF, infliximab; MTX-IR, inadequate response to MTX alone; n/s, not specified; PBO,
placebo; PPD, purified protein derivative; RCT, randomised controlled trial; RF, rheumatoid factor; RTX, rituximab; SJC, swollen joint count; TCZ, tocilizumab; TJC,
tender joint count; TNF, tumour necrosis factor
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Trial
(reference)
Treatment arm RF status
(%
positive)
Gender
(% F)
Mean
age
(years)
Mean
years
since
diagnosis
Mean n
of prior
DMARDs
% pts
on
NSAIDs
% pts on
corticoid
steriods
Mean
TJC
Mean
SJC
Mean pts
pain
1
(100-mm
VAS)
Mean pts
GA
2 (100-
mm VAS)
Mean phs
GA
3 (100-
mm VAS)
Mean
HAQ-
DI
Mean
CRP
(mg/l)
Mean
ESR
(mm/
h)
Abatacept studies
AIM [14,18] PBO + MTX;
ABA 10 mg/kg
every four weeks +
MTX
81.8 77.8 51.5 8.5 1.3 85.5 72.1 31.0 21.4 63.3 62.7 68.0 1.70 33 nr
78.5 81.7 50.4 8.9 1.2 82.6 68.5 32.3 22.1 65.9 62.8 67.4 1.70 28
Kremer et al.
2005, Kremer et
al. 2003 [16,17]
PBO + MTX 90.0 66.0 54.7 8.9 21% nr 67.2 29.2 21.8 65.2 62.8 63.3 1.00 32 nr
ABA 2 mg/kg every
four weeks + MTX
90.0 63.0 54.4 9.7 18.1% 67.6 28.2 20.2 64.5 59.4 61.0 1.00 32
ABA 10 mg/kg
every four weeks +
MTX
99.0 75.0 55.8 9.7 16.5% 60.0 30.8 21.3 62.1 60.1 62.1 1.00 29
ATTEST [15] ABA 10 mg/kg
every four weeks +
MTX
87.2 83.3 49.0 7.9 1.7 85.3 75.6 31.6 21.3 nr nr nr 1.80 31 49.4
PBO + MTX 77.3 87.3 49.4 8.4 1.8 84.5 70.0 30.3 20.1 1.80 27 47.0
INF 3 mg/kg every
eight weeks +MTX
84.8 82.4 49.1 7.3 1.7 86.1 71.5 31.7 20.3 1.70 33 47.8
Adalimumab studies
ARMADA [25] PBO + MTX mean IU/
liter +- SD
reported
82.3 56.0 11.1 3.0 nr nr 28.7 16.9 57.2 58.0 58.9 1.64 31 nr
ADA 20 mg every
other week + MTX
75.4 53.5 13.1 3.0 28.5 17.6 55.1 57.6 60.5 1.52 28
Adalimumab 40 mg
every other week +
MTX
74.6 57.2 12.2 2.9 28.0 17.3 53.0 56.9 58.7 1.55 21
ADA 80 mg every
other week + MTX
75.3 55.5 12.8 3.1 30.3 17.0 55.0 58.8 62.6 1.55 28
DE019 [24] ADA 40 mg every
other week + MTX
81.6 76.3 56.1 11.0 2.4 nr nr 27.3 19.3 55.9 52.7 62.0 1.45 18 nr
ADA 20 mg weekly
+ MTX
81.2 75.5 57.3 11.0 2.4 27.9 19.6 55.2 51.9 61.6 1.44 14
PBO + MTX 89.5 73.0 56.1 10.9 2.4 28.1 19.0 56.3 54.3 61.3 1.48 18
Certolizumab Pegol studies
RAPID I
[26,27,29]
PBO + MTX 82.8 83.9 52.2 6.2 1.4 nr nr 29.8 21.2 nr nr nr 1.70 16 45.0
CZP 200 mg every
other week + MTX
79.6 82.4 51.4 6.1 1.3 30.8 21.7 1.70 16 43.5
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8Table 2 Overview of patient characteristics (Continued)
CZP 400 mg every
other week + MTX
83.6 83.6 52.4 6.2 1.3 31.1 21.5 1.70 14 42.5
RAPID II [28,29] PBO + MTX 78.2 84.3 51.5 5.6 1.2 nr nr 30.4 21.9 59.9 59.9 65.7 1.60 14 40.8
CZP 200 mg every
other week + MTX
77.5 83.7 52.2 6.1 1.2 30.1 20.5 61.8 62.4 64.3 1.60 14 43.7
CZP 400 mg every
other week + MTX
75.5 78.0 51.9 6.5 1.3 30.0 21.0 60.5 61.1 62.8 1.60 13 39.1
Etanercept studies
Weinblatt et al.
1999 [32]
PBO + MTX 90.0 73.0 53.0 13.0 2.8 80.0 70.0 28.0 17.0 56.0 60.0 65.0 1.50 26 36.0
ETN 25 mg twice
weekly + MTX
84.0 90.0 48.0 13.0 2.7 75.0 53.0 28.0 20.0 50.0 60.0 60.0 1.50 22 25.0
TEMPO [30,31] PBO + MTX 71.0 79.0 53.0 6.8 2.3 86.0 64.0 33.1 22.6 nr nr nr nr 26 nr
ETN 25 mg twice
weekly
75.0 77.0 53.2 6.3 2.3 88.0 57.0 35.0 23.0 32
ETN 25 mg twice
weekly + MTX
76.0 74.0 52.5 6.8 2.3 88.0 62.0 34.2 22.1 30
Golimumab studies
GO-FORWARD
[33,34]
PBO + MTX 81.2 82.0 52.0 6.5 70.7
4 nr nr 21.0 12.0 57.0 53.0 56.5 1.25 8 nr
GOL 100 mg every
4 weeks
83.5 78.9 51.0 5.9 75.9 22.0 11.0 60.0 56.0 58.0 1.38 9
GOL 50 mg every 4
weeks + MTX
86.5 80.9 52.0 4.5 78.7 26.0 13.0 61.0 60.0 61.0 1.38 10
GOL 100 mg every
four weeks + MTX
84.3 80.9 50.0 6.7 75.3 23.0 12.0 64.0 59.0 61.0 1.38 9
Infliximab studies
ATTRACT
[35,36]
PBO + MTX 77.0 80.0 51.0 8.9 2.5 72.0 64.0 24.0 19.0 67.0 62.0 65.0 1.80 30 nr
INF 3 mg/kg every
eight weeks +MTX
84.0 81.0 56.0 8.4 2.8 79.0 63.0 32.0 19.0 70.0 66.0 61.0 1.80 31
INF 3 mg/kg every
four weeks +MTX
80.0 77.0 51.0 7.2 2.6 76.0 53.0 31.0 20.0 69.0 57.0 62.0 1.80 20
INF 10 mg/kg every
eight weeks +MTX
82.0 77.0 55.0 9.0 2.5 77.0 57.0 30.0 20.0 67.0 64.0 64.0 1.80 25
INF 10 mg/kg every
four weeks +MTX
82.0 73.0 52.0 8.7 2.5 68.0 65.0 35.0 23.0 66.0 60.0 60.0 1.50 24
Rituximab studies
DANCER [39,40] PBO + MTX 100
(efficacy
analyses)
80.0 51.1 9.3 2.2 nr nr 35.0 21.0 nr nr nr 1.70 33 40.0
RTX 500 mg * two
injections + MTX
100 83.0 51.4 11.1 2.5 33.0 22.0 1.80 32 45.0
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8Table 2 Overview of patient characteristics (Continued)
RTX 1,000 mg * two
injections + MTX
100 80.0 51.1 10.8 2.5 32.0 22.0 1.70 30 41.0
Edwards et al.
2004 [41]
PBO + MTX 100 80.0 54.0 11.0 2.6 nr nr 32.0 19.0 nr nr nr nr 32 52.0
RTX 1,000 mg * two
injections
100 73.0 54.0 9.0 2.5 34.0 21.0 26 47.0
RTX 1,000 mg * two
injections
+cyclophosphamide
100 83.0 53.0 10.0 2.6 33.0 19.0 40 55.0
RTX 1,000 mg * two
injections + MTX
100 75.0 54.0 12.0 2.5 32.0 23.0 29 53.0
Tocilizumab studies
OPTION [43,44] PBO + MTX 78.0 78.0 50.6 7.8 1.7 68.0 nr 32.8 20.7 57.3 63.6 63.7 1.50 24 49.7
TCZ 4 mg/kg every
four weeks + MTX
83.0 82.0 51.4 7.4 1.5 68.0 33.2 20.0 60.7 65.6 63.6 1.60 28 49.2
TCZ 8 mg/kg every
four weeks + MTX
71.0 85.0 50.8 7.5 1.5 66.0 31.9 19.5 59.9 64.8 64.0 1.60 26 51.2
LITHE [42] PBO + MTX nr nr nr nr nr nr nr nr nr nr nr nr 1.5 nr nr
TCZ 4 mg/kg every
four weeks + MTX
1.5
TCZ 8 mg/kg every
four weeks + MTX
1.5
The treatment arms in grey were not used in the network meta-analysis but are included as part of the trials.
1Patients assessment of pain (Pts Pain);
2Patients global assessment of disease activity (Pts GA);
3Physician global assessment of disease activity (Phs GA);
4% Patients with previous use of DMARD other than MTX.
ABA, abatacept; ADA, adalimumab; CRP, C-reactive protein; CZP, certolizumab pegol; DMARD, Disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; ETN, etanercept; GA, global assessment;
GOL, golimumab; HAQ, health assessment questionnaire; INF, infliximab; MTX, methotrexate; nr, not recorded; NSAID, non-steroidal anti-inflammatory drug; PBO, placebo; Pts, patients; RF, rheumatoid factor; RTX,
rituximab; SJC, swollen joint count; TCZ, tocilizumab; TJC, tender joint count;
No data for patient characteristics were available for the SERENE study.
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8Table 3 Reported data for HAQ CFB, ACR-50 and DAS28 < 2.6 at 24 and 52 weeks
Trial N Mean HAQ CFB at
24 weeks (SD)
Mean HAQ CFB at
52 weeks (SD)
ACR-50 r at
24 weeks
ACR-50 r at
52 weeks
DAS28 < 2.6 r
at 24 weeks
DAS28 < 2.6 r
at 52 weeks
Placebo + MTX
AIM [14,18] 219 -0.40 (0.59) -0.37 (0.59) 37 40 6 4
Kremer et al. 2005, Kremer
et al. 2003 [16,17]
119 -0.14 (0.49*) -0.10 (0.83*) 14 24 11 12
ATTEST [15] 110 -0.29 (0.22) 22 3
ARMADA [25] 62 -0.27 (0.57) 5
DE019 [24] 200 -0.24 (0.52) -0.25 (0.56) 19 19
RAPID I [26,27,29] 199 -0.17 (0.56) -0.18 (0.56) 15 15
RAPID II [28,29] 127 -0.14 (0.45) 4 1
Weinblatt et al. 1999 [32] 30 -0.40 (0.49*) 1
TEMPO [30,31] 228 -0.63 (1.08*) -0.63 (1.41*) 92 91 31 39
GO-FORWARD [33,34] 133 -0.13 (0.58) 18 8
ATTRACT [35,36] 88 -0.19 (0.49*) -0.17 (0.60*) 8
DANCER [39,40] 122 -0.28 (0.50) 16
Strand et al. 2006 [41] 40 -0.40 (0.62*) -0.30 (0.64*) 5 2
SERENE [37,38] 172 -0.19 (0.56*) -0.19
† (0.60*) 15 15 3 3
OPTION [43,44] 204 -0.34 (0.83*) 22 1
LITHE [42] 393 39 12
Abatacept + MTX
AIM [14,18] 433 -0.59 (0.62) -0.66 (0.62) 173 209 64 103
Kremer et al. 2005, Kremer
et al. 2003 [16,17]
115 -0.42 (0.49*) -0.47 (0.83*) 42 48 30 40
ATTEST [15] 156 -0.68 (0.22) -0.67 (0.62) 63 71 18 29
Adalimumab + MTX
ARMADA [25] 67 -0.62 (0.63) 37
DE019 [24] 207 -0.56 (0.52) -0.59 (0.57) 81 86
Certolizumab + MTX
RAPID I [26,27,29] 393 -0.58 (0.59) -0.60 (0.59) 146 147
RAPID II [28,29] 246 -0.50 (0.47) 80 23
Etanercept + MTX
Weinblatt et al. 1999 [32] 59 -0.70 (0.49*) 23
TEMPO [30,31] 231 -0.89 (1.08*) -0.97 (1.41*) 136 180 70 88
Golimumab + MTX
GO-FORWARD [33,34] 89 -0.47 (0.55) 33 18
Infliximab + MTX
ATTEST [15] 165 -0.53 (0.29) -0.59 (0.64) 61 60 21 20
ATTRACT [35,36] 86 -0.31 (0.49*) -0.32 (0.60*) 21
Rituximab + MTX
DANCER [39,40] 122 -0.49 (0.55) 41
Strand et al. 2006 [41] 40 -0.60 (0.92*) -0.60 (0.88*) 17 14
SERENE [37,38] 170 -0.42 (0.54*) -0.47 (0.60*) 44 61 15 19
Tocilizumab + MTX
OPTION [43,44] 205 -0.55 (0.82*) 90 47
LITHE [42] 398 145 127
*Standard deviation (SD) was estimated.
†No placebo value was available at 52 weeks for placebo so the values have been assumed equal to the values for 24 weeks.
ABA, abatacept; ADA, adalimumab; CFB, change from baseline; CZP, certolizumab pegol; ETN, etanercept; GOL, golimumab; INF, infliximab; N, number of patients
in trial; PBO, placebo; r, number of responders; RTX, rituximab; TCZ, tocilizumab
Guyot et al. Arthritis Research & Therapy 2011, 13:R204
http://arthritis-research.com/content/13/6/R204
Page 12 of 18included a DMARD-IR population rather than a MTX-
IR population as included in the other trials and also
showed high observed response rates in the control
group, which is substantially different from observed
findings in other studies. The patient selection criteria
in the TEMPO trials allowed for inclusion of patients
not treated with MTX, potentially explaining the high
response rate observed in the control arm. Removing
the TEMPO trial did not significantly impact on the
findings for the mean HAQ CFB at 24 weeks: abata-
cept was found to be comparable in efficacy to all bio-
logics, including etanercept (difference in HAQ CFB
vs. etanercept: 0.00 (95% CrI: -0.32; 0.33)). However,
excluding the TEMPO trial from the ACR-50 analysis
at 24 weeks did have an impact on the results. By
excluding this trial the heterogeneity was reduced and
goodness of fit statistics suggested the use of a fixed
effects model. This resulted in smaller credible inter-
vals around the point estimates. As a result, abatacept
was found to be more efficacious than placebo (OR:
3.31, 95% CrI: 2.47; 4.48) although less efficacious than
certolizumab pegol (OR: 0.37, 95% CrI: 0.20; 0.64),
adalimumab (OR: 0.43, 95% CrI: 0.24; 0.75), etanercept
(OR: 0.12, 95% CrI: 0.00; 0.82) and tocilizumab (OR:
0.50, 95% CrI: 0.27; 0.91). Abatacept showed compar-
able efficacy to golimumab, infliximab and rituximab.
Differences in trial design that might explain these
findings are described in the discussion section.
The TEMPO trial did not report HAQ data at 52
weeks and was the only trial reporting ACR-50 data for
etanercept at 52 weeks, and the only trial reporting
DAS28 defined remission data for etanercept at both
follow-ups, limiting the evaluation of excluding TEMPO
on these endpoints.
In the base case analysis all randomised patients were
included for the AIM study, although patients included
from one site were excluded from the efficacy analyses
because of protocol violations. Its impact on the findings
was evaluated in a sensitivity analysis and did not
change the relative efficacy of abatacept to other biolo-
gic agents (data not reported).
Including the data for the SERENE [37,38] study, eval-
uating rituximab, and the LITHE [42] study, evaluating
tocilizumab did not substantially impact the results. The
SERENE study presents HAQ CFB, ACR-50 and DAS28
< 2.6 data at both follow-ups. The LITHE study only
reports ACR-50 and DAS28 defined remission response
rates at 52 weeks. Abatacept showed comparable efficacy
versus rituximab at 24 weeks: (mean difference in HAQ
CFB: -0.08 95% CrI: -0.24; 0.10), ACR-50 (OR: 0.87, 95%
CrI: 0.31; 2.30), DAS28 < 2.6 (OR: 0.80, 95% CrI: 0.07;
8.20), and at 52 weeks (mean difference in HAQ CFB:
-0.01, 95% CrI: -0.36; 0.31), ACR-50 (OR: 0.55, 95% CrI:
0.13; 1.78), DAS28 < 2.6 (OR: 1.09, 95% CrI: 0.04;
30.72). Abatacept demonstrated comparable efficacy ver-
sus tocilizumab at 52 weeks (ACR-50 (OR: 0.73, 95%
Table 4 Relative efficacy versus abatacept + MTX at 24/26 and 48/54 weeks
Treatment effect relative to
Abatacept + MTX
Difference in mean
HAQ CFB
at 24/26 weeks
(95% CrL)*
Difference in mean
HAQ CFB
at 48/54 weeks
(95% CrL)**
OR for
ACR-50
at 24/26
weeks
(95% CrL)*
OR for
ACR-50
at 48/54
weeks
(95% CrL)
**
OR for DAS28
< 2.6
at 24/26
weeks
(95% CrL)*
OR for DAS28
< 2.6
at 48/54
weeks
(95% CrL)*
Placebo + MTX -0.30
(-0.41; -0.18)
-0.29
(-0.38; -0.21)
3.37
(1.49; 8.06)
3.84
(2.84; 5.26)
4.77
(1.60; 15.78)
8.82
(1.50; 57.83)
Adalimumab + MTX 0.03
(-0.16; 0.24)
0.05
(-0.09; 0.18)
0.40
(0.09; 1.50)
0.56
(0.29; 1.03)
Certolizumab Pegol + MTX 0.08
(-0.09; 0.28)
0.13
(-0.00; 0.26)
0.35
(0.08; 1.33)
0.51
(0.26; 0.96)
0.26
(0.01; 3.90)
Etanercept + MTX -0.02
(-0.24; 0.21)
0.05
(-0.22; 0.32)
1.05
(0.17; 3.24)
0.72
(0.43; 1.19)
1.69
(0.21; 15.80)
2.94
(0.14; 67.12)
Golimumab + MTX 0.04
(-0.21; 0.30)
0.87
(0.16; 5.15)
1.18
(0.13; 11.66)
Infliximab + MTX -0.11
(-0.29; 0.08)
-0.11
(-0.22; 0.01)
1.31
(0.27; 7.61)
1.40
(0.93; 2.10)
0.88
(0.09; 7.76)
1.68
(0.14; 21.23)
Rituximab + MTX -0.09
(-0.31; 0.14)
0.01
(-0.34; 0.35)
0.85
(0.20; 3.47)
0.31
(0.04; 1.37)
Tocilizumab + MTX -0.09
(-0.35; 0.18)
0.51
(0.10; 2.88)
0.05
(0.00; 0.79)
Note: for HAQ CFB, negative values indicate a trend towards a clinical benefit for abatacept. For ACR-50 and DAS28 < 2.6, an OR > 1 indicates a trend towards a
clinical benefit for abatacept.
* Results based on a random effects model. ** Results based on a fixed effects model.
OR, odds ratio; 95% CrL, 95% credible limits
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Page 13 of 18CrI: 0.17; 3.12), DAS28 < 2.6 (OR: 0.58, 95% CrI: 0.03;
14.23)).
Discussion
An e t w o r km e t a - a n a l y s i sb a s ed on a systematic review
of the literature was performed to estimate the relative
efficacy of abatacept compared with other relevant
biologic DMARDs in the treatment of RA patients
with insufficient response to MTX. The results of the
network meta-analysis showed that abatacept is
expected to be more efficacious than placebo and
show comparable efficacy relative to the other biologic
DMARDs in combination with MTX. The primary
outcome in the present study was the reduction in
functional status as measured by the HAQ score,
which is commonly used in economic modeling of RA
since this can be translated into required utility values
by means of published algorithms. Also, the clinically
relevant endpoints ACR-50 and DAS28-defined remis-
sion (< 2.6) at 24 weeks and 52 weeks were analysed.
Not all trials reported findings on all evaluated
endpoints. The decision was made to include all avail-
able data leading to differences in evidence used
across endpoints.
The analysis of DAS28-defined remission at 24 weeks
showed comparable findings to other biologic agents for
abatacept, except in the case of tocilizumab. It should
be noted that tocilizumab, due to its mechanism of
action, has a direct effect on the CRP-level and, there-
fore, is expected to show more efficacy on this endpoint.
Also, a low number of patients in remission were
observed in the placebo arms across the trials, making
the indirect treatment comparison susceptible to small
differences in the placebo arms. As a consequence,
results should be interpreted cautiously.
Although the TEMPO trial included different patients,
it was decided to include this study based on the fact
that TEMPO is the pivotal trial for etanercept. Had
TEMPO been excluded from the base case, data for eta-
nercept would have been based solely on a relatively old
and small trial (89 patients) by Weinblatt (1999) [32],
potentially biasing the findings in favor of etanercept.
Table 5 Adjusted absolute efficacy for biologic DMARDS + MTX at 24/26 and 48/54 weeks
Treatments
relative to
effect
Absolute
HAQ CFB
at 24/26
weeks
(95% CrL)
*
Absolute
HAQ CFB
at 48/54
weeks
(95% CrL)
**
Proportion (%) of
patients with ACR-50
at 24/26 weeks
(95% CrL) *
Proportion (%) of
patients with ACR-50
at 48/54 weeks
(95% CrL)**
Proportion (%) of
patients with DAS28 <
2.6
at 24/26 weeks
(95% CrL)*
Proportion (%) of
patients with DAS28 <
2.6
at 48/54 weeks
(95% CrL)*
Placebo + MTX -0.29
(-0.31;
-0.26)
-0.29
(-0.34;
-0.24)
11.9%
(9.7%; 14.0%)
12.5%
(9.4%; 15.5%)
2.6%
(1.4%; 4.1%)
7.0%
(4.7%; 9.8%)
Adalimumab +
MTX
-0.61
(-0.77;
-0.46)
-0.63
(-0.74;
-0.51)
53.5%
(28.0%; 77.9%)
49.5%
(35.9%; 63.5%)
Certolizumab
Pegol + MTX
-0.67
(-0.82;
-0.53)
-0.71
(-0.81;
-0.61)
57.3%
(31.2%; 79.9%)
51.7%
(38.1%; 66.1%)
33.4%
(4.4%; 90.0%)
Etanercept +
MTX
-0.56
(-0.75;
-0.38)
-0.63
(-0.87;
-0.39)
30.7%
(15.6%; 65.2%)
43.2%
(31.8%; 54.9%)
6.9%
(1.0; 31.5%)
18.7%
(1.8%; 73.3%)
Golimumab +
MTX
-0.63
(-0.86;
-0.39)
34.6%
(9.7%; 69.2%)
9.6%
(1.4%; 42.4%)
Infliximab +
MTX
-0.48
(-0.62;
-0.33)
-0.48
(-0.59;
-0.36)
26.0%
(6.6%; 57.4%)
28.1%
(19.4%; 38.3%)
12.6%
(1.9%; 53.3%)
28.8%
(1.9%; 89.5%)
Rituximab +
MTX
-0.49
(-0.68;
-0.31)
-0.59
(-0.91;
-0.27)
35.3%
(14.8%; 61.9%)
64.1%
(32.4%; 91.3%)
Tocilizumab +
MTX
-0.49
(-0.73;
-0.26)
47.5%
(16.1%; 78.6%)
71.0%
(19.0%; 98.9%)
Abatacept +
MTX
-0.58
(-0.70;
-0.46)
-0.58
(-0.66;
-0.50)
31.7%
(15.9%; 50.6%)
35.4%
(27.3%; 43.3%)
11.3%
(3.7%; 28.8%)
40.2%
(10.4%; 80.3%)
Note: For HAQ CFB, negative values indicate improvement.
* Results based on a random effects model. ** Results based on a fixed effects model.
95% CrL, 95% credible limits
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Page 14 of 18Other limitations in comparability of study and patient
characteristics were observed with the adalimumab, goli-
mumab and certolizumab pegol trials. The adalimumab
studies included an early escape for non-responders [24]
while the certolizumab pegol studies specifically with-
drew patients who did not show an ACR20 response at
weeks 12 and 14 [26-29]. Furthermore, the golimumab
[33,34] and tocilizumab [43,44] studies provided rescue
therapy for patients who did not achieve at least 20%
improvement in both Tender Joint Count and Swollen
Joint Count by week 16. The impact associated with the
adalimumab, golimumab and certolizumab pegol studies
was not explored in scenario analyses, as excluding
these studies would have removed the treatments from
the analysis and this would not have provided additional
information. Furthermore, there is currently no consen-
sus on how to correct for these differences in trial
design.
All patients in the studies received methotrexate in
the trial, independent of whether they were assigned to
the placebo or intervention arm. The fact that optimal
methotrexate dosing was decided by the investigator
and that the trials differ in specification of minimal
methotrexate dose may result in differences across the
trials. In turn, this may have had interaction with the
observed effect for the biologic agents and, therefore, is
potentially introducing bias in the analysis. Unfortu-
nately, we were unable to correct for this since metho-
trexate details are lacking.
A recent network meta-analysis of tocilizumab and
other biologic agents in patients who have an inade-
quate response to conventional DMARDs or MTX [46]
suggests that tocilizumab has a better overall response
than TNF-a inhibitors and abatacept, whereas our ana-
lyses suggest comparable efficacy. The apparent distinc-
tion may be attributable to differences in the selection
criteria for relevant studies (MTX vs. conventional
DMARDs background treatment) and, therefore, the evi-
dence base and analysis techniques (fixed versus random
approaches). The TOWARD trial [47] was not included
in our analyses and no data on HAQ score were avail-
able for the LITHE trial. Similarly, despite important
differences in the study selection process, the Cochrane
collaboration found that abatacept, adalimumab, etaner-
cept, infliximab and rituximab showed comparable effi-
cacy in patients with RA [48]. The Cochrane
collaboration also performed a network meta-analysis
on the safety of the biologic agents [49]. This study
-0.8 -0.6 -0.4 -0.2 0.00 .2 0.4
Treatment better than placebo
Abatacept + MTX vs Placebo + MTX
Tocilizumab + MTX vs Placebo + MTX
Rituximab + MTX vs Placebo + MTX
Infliximab + MTX vs Placebo + MTX
Golimumab + MTX vs Placebo + MTX
Etanercept + MTX vs Placebo + MTX
Certolizumab pegol + MTX vs Placebo + MTX
Adalimumab + MTX vs Placebo + MTX
time in weeks: mean HAQ CFB (95%CrI)
24: -0.33 (-0.49; -0.17)
52: -0.34 (-0.45; -0.23)
24: -0.38 (-0.53; -0.24)
52: -0.42 (-0.52; -0.32)
24: -0.28 (-0.47; -0.09)
52: -0.34 (-0.60; -0.08)
24: -0.34 (-0.57; -0.11)
24: -0.19 (-0.31; -0.07)
52: -0.21 (-0.40; -0.02)
24: -0.21 (-0.40; -0.02)
52: -0.30 (-0.63; 0.04)
24: -0.21 (-0.44; 0.03)
24: -0.30 (-0.41; -0.18)
52: -0.29 (-0.38; -0.21)
-0.8 -0.6 -0.4 -0.2 0.00 .2 0.4
Treatment better than placebo
Abatacept + MTX vs Placebo + MTX
Tocilizumab + MTX vs Placebo + MTX
Rituximab + MTX vs Placebo + MTX
Infliximab + MTX vs Placebo + MTX
Golimumab + MTX vs Placebo + MTX
Etanercept + MTX vs Placebo + MTX
Certolizumab pegol + MTX vs Placebo + MTX
Adalimumab + MTX vs Placebo + MTX
time in weeks: mean HAQ CFB (95%CrI)
24: -0.33 (-0.49; -0.17)
52: -0.34 (-0.45; -0.23)
24: -0.38 (-0.53; -0.24)
52: -0.42 (-0.52; -0.32)
24: -0.28 (-0.47; -0.09)
52: -0.34 (-0.60; -0.08)
24: -0.34 (-0.57; -0.11)
24: -0.19 (-0.31; -0.07)
52: -0.21 (-0.40; -0.02)
24: -0.21 (-0.40; -0.02)
52: -0.30 (-0.63; 0.04)
24: -0.21 (-0.44; 0.03)
24: -0.30 (-0.41; -0.18)
52: -0.29 (-0.38; -0.21)
Figure 2 Relative HAQ CFB of each biologic versus placebo. CFB, change from baseline; HAQ, Health Assessment Questionnaire; MT,:
Methotrexate.
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Page 15 of 18revealed that abatacept was associated with a signifi-
cantly lower risk of serious adverse events compared to
most other biologics and was significantly less likely
than infliximab and tocilizumab to be associated with
serious infections. When comparing different treat-
ments, safety should always be considered in addition to
efficacy. In our study no evaluation of safety was per-
formed as this would have required a different search
strategy. Finally, a systematic review [50] followed by
several meta-analyses of nine biological DMARDS
(including abatacept) vs. placebo was performed and
used to inform the EULAR recommendation [51]. In
this publication, all biological DMARDs + MTX combi-
nations were found to be more efficacious than placebo
+ MTX in the treatment of patients with an inadequate
response to MTX.
Conclusions
Currently it is not possible to predict, on an individual
basis, which patient will respond to a particular therapy.
This is a significant unmet need which is the goal of
much research effort. In the absence of reliable biomar-
kers on which to base individual treatment decisions, it is
important that patients have access to the full range of
biologic therapeutics with different mechanisms of action
and proven efficacy. This network meta-analysis strongly
suggests that abatacept in combination with MTX is
superior to placebo and is comparable to other biologic
DMARDs for the reduction in disability (HAQ CFB) of
RA for at least a year of treatment in patients with active
disease despite previous treatment with MTX. Abatacept
in combination with MTX is also expected to be superior
to placebo and comparable to all other biologic agents
for ACR-50, with the exception of certolizumab pegol at
52 weeks, although this needs to be interpreted with cau-
tion due to the earlier described difference in trial design,
and comparable efficacy in DAS28 defined remission at
24 weeks (except for tocilizumab, which can be explained
by the causal relation with the CRP level).
Based on its unique mechanism of action, relative effi-
cacy and clinical trial safety profile [14-18], abatacept is
a suitable alternative to currently licensed biologic
DMARDs, meaning that abatacept in combination with
MTX should be available to patients with RA, which is
refractory to MTX alone.
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